{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:25:31Z","timestamp":1769603131621,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T00:00:00Z","timestamp":1539302400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112082"],"award-info":[{"award-number":["70112082"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10549-018-5009-2","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T14:32:34Z","timestamp":1539354754000},"page":"429-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?"],"prefix":"10.1007","volume":"173","author":[{"given":"Andr\u00e9","family":"Hennigs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melitta","family":"K\u00f6pke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Fei\u00dft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Rezai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Nitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareike","family":"Moderow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Golatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Heil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,12]]},"reference":[{"issue":"4","key":"5009_CR1","doi-asserted-by":"publisher","first-page":"30716","DOI":"10.1056\/NEJMoa1415340","volume":"373","author":"TJ Whelan","year":"2015","unstructured":"Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A et al (2015) Regional nodal irradiation in early-stage breast cancer. N Engl J Med 373(4):30716","journal-title":"N Engl J Med"},{"issue":"17","key":"5009_CR2","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1200\/JCO.2009.24.7643","volume":"28","author":"V Moebus","year":"2010","unstructured":"Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874\u20132880","journal-title":"J Clin Oncol"},{"key":"5009_CR3","unstructured":"Network NCC. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Breast Cancer 2016. 1(2016)"},{"issue":"6797","key":"5009_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747\u2013752","journal-title":"Nature"},{"issue":"8","key":"5009_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717\u2013729","journal-title":"N Engl J Med"},{"issue":"20","key":"5009_CR6","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1200\/JCO.2015.63.5383","volume":"34","author":"O Gluz","year":"2016","unstructured":"Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M et al (2016) West German Study Group phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34(20):2341\u20132349","journal-title":"J Clin Oncol"},{"issue":"6","key":"5009_CR7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349(6):546\u2013553","journal-title":"N Engl J Med"},{"issue":"10","key":"5009_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927\u2013933","journal-title":"Lancet Oncol"},{"issue":"6","key":"5009_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(13)70076-7","volume":"14","author":"T DiSipio","year":"2013","unstructured":"DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500\u2013515","journal-title":"Lancet Oncol"},{"issue":"3","key":"5009_CR10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","volume":"252","author":"AE Giuliano","year":"2010","unstructured":"Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM et al (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252(3):426\u2013432; discussion 32\u20133","journal-title":"Ann Surg"},{"issue":"3","key":"5009_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"AE Giuliano","year":"2016","unstructured":"Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P et al (2016) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg 264(3):413\u2013420","journal-title":"Ann Surg"},{"issue":"10","key":"5009_CR12","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318(10):918\u2013926","journal-title":"JAMA"},{"issue":"8","key":"5009_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ejso.2012.04.018","volume":"38","author":"U Guth","year":"2012","unstructured":"Guth U, Myrick ME, Viehl CT, Schmid SM, Obermann EC, Weber WP (2012) The post ACOSOG Z0011 era: does our new understanding of breast cancer really change clinical practice? Eur J Surg Oncol 38(8):645\u2013650","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"5009_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/107327481201900403","volume":"19","author":"M Shah-Khan","year":"2012","unstructured":"Shah-Khan M, Boughey JC (2012) Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial. Cancer Control 19(4):267\u2013276","journal-title":"Cancer Control"},{"issue":"9","key":"5009_CR15","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1245\/s10434-011-1857-2","volume":"18","author":"M Morrow","year":"2011","unstructured":"Morrow M, Giuliano AE (2011) To cut is to cure: can we really apply Z11 in practice? Ann Surg Oncol 18(9):2413\u20132415","journal-title":"Ann Surg Oncol"},{"key":"5009_CR16","unstructured":"WBC, Westdeutsches Brust-Centrum GmbH. Benchmarking WBC\u20132014, Jahresbericht, Kennzahlen. 2015"},{"issue":"9","key":"5009_CR17","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206\u20132223","journal-title":"Ann Oncol"},{"issue":"21","key":"5009_CR18","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1200\/JCO.2010.33.4714","volume":"29","author":"BS Abdulkarim","year":"2011","unstructured":"Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S (2011) Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 29(21):2852\u20132858","journal-title":"J Clin Oncol"},{"issue":"21","key":"5009_CR19","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","volume":"88","author":"B Fisher","year":"1996","unstructured":"Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529\u20131542","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"5009_CR20","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1200\/JCO.1996.14.7.1982","volume":"14","author":"B Fisher","year":"1996","unstructured":"Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C et al (1996) Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14(7):1982\u20131992","journal-title":"J Clin Oncol"},{"issue":"4","key":"5009_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23 \u2013 01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297\u2013305","journal-title":"Lancet Oncol"},{"issue":"12","key":"5009_CR22","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303\u20131310","journal-title":"Lancet Oncol"},{"issue":"4","key":"5009_CR23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","volume":"43","author":"A Savolt","year":"2017","unstructured":"Savolt A, Peley G, Polgar C, Udvarhelyi N, Rubovszky G, Kovacs E et al (2017) Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol 43(4):672\u2013679","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"5009_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1245\/s10434-012-2569-y","volume":"20","author":"M Sola","year":"2013","unstructured":"Sola M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R et al (2013) Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048\/13\/2000. Ann Surg Oncol 20(1):120\u2013127","journal-title":"Ann Surg Oncol"},{"issue":"18","key":"5009_CR25","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2008.19.5750","volume":"27","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY et al (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 27(18):2946\u20132953","journal-title":"J Clin Oncol"},{"issue":"18_suppl","key":"5009_CR26","doi-asserted-by":"publisher","first-page":"CRA506","DOI":"10.1200\/jco.2010.28.18_suppl.cra506","volume":"28","author":"AE Giuliano","year":"2010","unstructured":"Giuliano AE, McCall LM, Beitsch PD, Whitworth PW, Morrow M, Blumencranz PW et al (2010) ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol 28(18_suppl):CRA506\u2013CRA506RA","journal-title":"J Clin Oncol"},{"key":"5009_CR27","unstructured":"Interdisziplin\u00e4re S3-Leitlinie f\u00fcr die Fr\u00fcherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms 12\/2017. http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/032-045OLl_S3_Mammakarzinom_2017-12.pdf"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-5009-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-5009-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-5009-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T22:36:18Z","timestamp":1662244578000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-5009-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,12]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["5009"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-5009-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,12]]},"assertion":[{"value":"24 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There are no conflicts of interests (e.g. employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications\/registrations or grants or other funding with regard to this study) for any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of the University of Heidelberg and was conducted in accordance with the Declaration of Helsinki. The study was deemed to be without risk, including only anonymised analysis of routinely collected data; consequently, the ethics committee of the University of Heidelberg did not request approval for consent for this designated analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants within the data acquisition of the benchmarking process to analyse the anonymised data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}